D SiO2, 3 g, one hundred CH2Cl2, 1 MeOH/ CH2Cl2) to afford coupled

D SiO2, 3 g, one hundred CH2Cl2, 1 MeOH/ CH2Cl2) to afford coupled PAK Formulation pyrimidine 32 as a pale white powder (0.065 g, 78 ); TLC Rf = 0.two (5 MeOH/CH2Cl2); mp 130.9-133.1 ; 1H NMR (500 MHz, CDCl3) 7.73-7.70 (m, 2H), 7.69-7.63 (m, 3H), 7.19 (dd, J = 7.8, 1.7 Hz, 1H), 7.05 (d, J = 1.7 Hz, 1H), five.24 (s, 2H), 4.98 (s, 2H), four.45 (q, J = 7.0 Hz, 1H), three.94 (s, 3H), 2.71 (q, J = 7.6 Hz, 2H), 1.55 (d, J = 7.0 Hz, 3H), 1.24 (t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) 173.four, 164.five, 160.eight, 156.eight, 145.7, 139.three, 132.8, 132.five, 128.five, 127.9, 119.9, 119.1, 111.1, 109.six, 101.9, 90.8, 74.8, 55.six, 29.8, 26.9, 23.0, 12.7; IR (neat cm-1) 3464, 3428, 3332, 3188, 3029, 2925, 2775, 2546, 1651, 1548, 1445, 1286, 1008, 735, 557; HRMS (DART, M+ + H) m/z 398.1983, (calculated for C24H24N5O, 398.1981). HPLC (a) tR = 19.2 min, 99.6 ; (b) tR = 17.5 min, 99.5 . Carbamic Acid 4-[3-(two,4-Diamino-6-ethyl-pyrimidin-5-yl)-1methyl-prop-2-ynyl]-3-methoxy-biphenyl-4-yl Ester (33). According to the common Sonogahisra coupling procedure, ethyl-iodopyrimidine (0.055 g, 0.21 mmol), CuI (0.008 g, 0.04 mmol, 21 mol ), Pd(PPh3)2Cl2 (0.015 g, 0.021 mmol, 10 mol ), and alkyne 23 (0.092 g, 0.31 mmol) have been reacted in DMF/Et3N (1 mL every single) at 60 for 12 h. Right after the mixture was cooled, the dark reddish brown remedy was concentrated, and the item was purified by flash chromatography (SiO2, five g, two MeOH/CHCl3) to afford coupled pyrimidine 33 as a pale white powder (0.076 g, 84 ) followed by reverse phase flash chromatography (NH2 capped SiO2, 3 g, 100 CH2Cl2, 1 MeOH/ CH2Cl2) for biological PDE11 manufacturer evaluation: TLC Rf = 0.07 (5 MeOH/ CH2Cl2); 1H NMR (500 MHz, MeOD) 7.53 (d, J = 7.8 Hz, 1H), 7.46 (d, J = 8.6 Hz, 2H), 7.13 (dd, J = 7.eight,1.60, 1H), 7.11 (d, J = 1.three Hz, 1H), 6.85 (d, J = eight.six Hz, 2H), four.41 (q, J = 6.9 Hz, 1H), 3.93 (s, 3H), 2.67 (q, J = 7.6 Hz, 2H), 1.52 (d, J = 7.0 Hz, 3H), 1.22 (t, J = 7.six Hz, 3H); 13C NMR (125 MHz, MeOD) 173.five, 166.1, 162.two, 158.3, 157.9, 142.7, 133.8, 130.9, 129.1, 128.9, 119.9, 116.7, 110.1, 103.2, 91.four, 74.9, 56.2, 30.4, 27.9, 23.4, 13.3; IR (neat cm-1) 3477, 3386, 3336, 3195, 2970, 2929, 2873, 2361, 2023, 1603, 1437, 1217, 1027, 813. HRMS (ESI, M+ + Na) m/z 455.1947 (calculated for C24H26N5NaO3, 455.1928). HPLC (a) tR = 6.8 min, 98 ; (b) tR = eight.two min, 98.7 . 4-[3-(2,4-Diamino-6-ethyl-pyrimidin-5-yl)-1-methyl-prop-2ynyl]-3-methoxy-biphenyl-4-carboxylic Acid Methyl Ester (34). In accordance with the basic Sonogahisra coupling procedure, ethyliodopyrimidine (0.061g, 0.23 mmol), CuI (0.009 g, 0.05 mmol, 21 mol ), Pd(PPh3)2Cl2 (0.016 g, 0.023 mmol, ten mol ), and alkyne 24 (0.100 g, 0.34 mmol) have been reacted in DMF/Et3N (1 mL each) at 60 for 12 h. Soon after the mixture was cooled, the dark reddish brown solution was concentrated, and also the product was purified by flash chromatography (SiO2, 5g, two MeOH/CHCl3) to afford coupled pyrimidine 34 as a pale white powder (0.077 g, 77 ) followed by reverse phase flash chromatography (NH2 capped SiO2, 3 g, one hundred CH2Cl2, 1 MeOH/CH2Cl2): TLC Rf = 0.1 (5 MeOH/CH2Cl2); mp 168.2-170.eight ; 1H NMR (500 MHz, CDCl3) eight.08 (d, J = eight.55 Hz, 2H), 7.64-7.60 (m, 3H), 7.21 (dd, J = 7.eight, 1.6 Hz, 1H), 7.08 (d, J = 1.5 Hz, 1H), five.15 (s, 2H), four.84 (s, 2H), four.43 (q, J = 7.0 Hz, 1H), 3.93 (s, 3H), 3.92 (s, 3H), two.70 (q, J = 7.six Hz, 2H), 1.54 (d, J = 7.0 Hz, 3H), 1.23 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) 173.5, 167.two, 164.five, 160.eight, 156.7, 145.7, 140.2, 131.9, 130.3, 129.2, 128.3, 127.2, 120.0, 109.7, 102.1, 90.9, 74.7, 55.8, 52.4, 29.9, 26.9, 2.